Opinion|Videos|June 26, 2024
Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial
Results from the monarchE trial are analyzed by Hope Rugo, MD, and Joyce O'Shaughnessy, MD.
Advertisement
Video content above is prompted by the following:
- Abemaciclib is recommended by NCCN in this setting based on the monarchE trial, which recently released its 5-year long-term data in January.
- Describe the updated survival data, including both invasive disease-free survival and overall survival. How have these survival rates evolved with each annual analysis?
- Please highlight the follow-up time of patients.
- Are there specific subgroups of patients within the monarchE trial who derived particular benefit from the addition of abemaciclib?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Novel Iberdomide Regimen in RRMM
2
Iberdomide Approval Elevates MRD’s Role in Myeloma: Prerna Mewawalla, MD
3
AI Model Outperforms Apnea-Hypopnea Index in Predicting Sleep Apnea Mortality Risk
4
IL-17 Signaling Bridges Psoriasis and Cardiometabolic Risk, Review Finds
5